Surgery is standard for early-stage HPV HNC, but deciding who needs adjuvant therapy relies on clinicopathologic features with limited accuracy. These are static, backward-looking variables —they tell us what was in the specimen, not whether disease remains. We need better tools
Big day for our lab! New paper using our HPV-DeepSeek assay, an ultrasensitive HPV WGS-based liquid biopsy for MRD detection in HPV head & neck cancer, is out today in @ScienceTM 🧵
🔗 science.org/doi/10.1126/scit…
Celebrating MGH End-of-Year Fellow Graduation! 🎉 What an incredible journey it has been—filled with education, mentorship, professional growth. Most importantly, it brought countless unforgettable moments of laughter and joy. #Cytopath#Cytology#Pathology#PathX
New in #CytoSource: Cysteine-mapping efforts offer new tools for drug development and discovery💊
Research groups are characterizing cysteine binding and reactivity traits to provide important new starting points for drug design.
acsjournals.onlinelibrary.wi…#CytoPath@bfaquin